Purpose: The role of thyroglobulin (Tg) in predicting death and recurrence risk in patients with poorly differentiated thyroid carcinoma (PDTC) is not well established. We aimed to analyze Tg levels following total thyroidectomy and adjuvant radioiodine treatment (RAI) in PDTC patients and correlate Tg levels with survival and recurrence. Methods: A retrospective analysis was conducted on 101 patients with PDTC who were treated between 1986 and 2010. Among them, 38 had no distant metastases at presentation, were managed by total thyroidectomy and adjuvant RAI, and had negative anti-Tg antibodies. An unstimulated Tg level < 1 ng/mL was used as a cut-off point for undetectable Tg levels. Association of patient and tumor characteristics with Tg levels was examined by χ2 test. Overall survival, disease-specific survival (DSS), and recurrence-free survival (RFS), stratified by Tg levels, were calculated by the Kaplan-Meier method and compared by the log-rank test. Results: Compared to patients with undetectable Tg, cases with detectable Tg had a lower probability of achieving free surgical margins (21.7 vs. 46.7%; p = 0.04), higher node status (73.3 vs. 21.8%; p = 0.005), decreased 5-year DSS (65 vs. 100%; p = 0.009), and worse 5-year RFS (32 vs. 84%, p = 0.010), with a significant number of patients having a recurrence in the first year (50 vs. 12.5%; p = 0.021). Patients with detectable Tg levels also showed worse locoregional (55.6 vs. 90.9%; p = 0.014) and distant control (5-year distant control of 46.9 vs. 91%; p = 0.017). Conclusions: Our results suggest that detectable Tg levels after surgery and RAI in a subset of PDTC patients appear to predict a higher rate of death and recurrence.

1.
Faggin JA, Wells SA: Biologic and clinical perspectives on thyroid cancer. N Engl J Med 2016; 375: 1054–1067.
2.
Sanders EM Jr, LiVolsi VA, Brierley J, Shin J, Randolph GW: An evidence-based review of poorly differentiated thyroid cancer. World J Surg 2007; 31: 934–945.
3.
Ibrahimpasic T, Ghossein R, Carlson DL, Nixon I, Palmer FL, Shaha AR, et al: Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab 2014; 99: 1245–1252.
4.
Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, et al: Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 2004; 100: 950–957.
5.
Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al: Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers J Clin Invest 2016; 126: 1052–1066.
6.
DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. Lyon, IARC, 2004.
7.
Volante M, Bussolati G, Papotti M: The story of poorly differentiated thyroid carcinoma: from Langhans’ description to the Turin proposal via Juan Rosai. Semin Diagn Pathol 2016; 33: 277–283.
8.
Killeen RM, Barnes L, Watson CG, Marsh WL, Chase DW, Schuller DE: Poorly differentiated (“insular”) thyroid carcinoma. Report of two cases and review of the literature. Arch Otolaryngol Head Neck Surg 1990; 116: 1082–1086.
9.
Ibrahimpasic T, Ghossein R, Carlson DL, Nixon IJ, Palmer FL, Patel SG, et al: Undetectable thyroglobulin levels in poorly differentiated thyroid carcinoma patients free of macroscopic disease after initial treatment: are they useful? Ann Surg Oncol 2015; 22: 4193–4197.
10.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds): AJCC Cancer Staging Manual, ed 7. New York, Springer, 2010.
11.
Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, et al: Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007; 31: 1256–1264.
12.
Sakamoto A, Kasai N, Sugano H: Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983; 52: 1849 –1855.
13.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167–1214.
14.
Hiltzik D, Carlson D, Tuttle RM, Chuai S, Ishill N, Shaha A, et al: Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 2006; 106: 1286–1295.
15.
Gnemmi V, Renaud F, Do Cao C, Salleron J, Lion G, Wemeau JL, et al: Poorly differentiated thyroid carcinomas: application of the Turin proposal provides prognostic results similar to those from the assessment of high-grade features. Histopathology 2014; 64: 263–273.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.